淋巴瘤 中国就医指南

Lymphoma is a heterogeneous group of malignant neoplasms originating from lymphoid tissue—primarily B cells, but also T cells and natural killer (NK) cells—within the immune system. It is broadly classified into two major categories: Hodgkin lymphoma (HL), characterized by the presence of Reed-Sternberg cells, and non-Hodgkin lymphoma (NHL), which encompasses over 90 distinct subtypes (e.g., diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma) with varying biological behaviors, clinical courses, and therapeutic responses. Pathogenesis involves cumulative genetic alterations—including chromosomal translocations (e.g., BCL2 in follicular lymphoma), somatic hypermutation errors, epigenetic dysregulation, and chronic antigenic stimulation—that disrupt normal lymphocyte proliferation, differentiation, and apoptosis. Immune dysfunction (e.g., HIV infection, post-transplant immunosuppression) and persistent viral infections (EBV, HTLV-1, HCV) further contribute to malignant transformation. Epidemiologically, lymphoma is the seventh most common cancer globally and the most frequent hematologic malignancy. In China, age-standardized incidence rates are approximately 5.2 per 100,000 for NHL and 0.7 per 100,000 for HL, with NHL incidence rising steadily—particularly among adults aged 60–75 years. Key risk factors include advanced age, male sex, autoimmune disorders (e.g., Sjögren’s syndrome, rheumatoid arthritis), immunosuppressive therapy, certain occupational exposures (e.g., pesticides, benzene), and familial predisposition. Lymphoma profoundly impacts quality of life: patients commonly experience debilitating fatigue, night sweats, unexplained weight loss, pruritus, and recurrent infections; psychological burden—including anxiety, depression, and treatment-related uncertainty—is prevalent; and long-term survivors may face late effects such as secondary cancers, cardiovascular toxicity, infertility, and neurocognitive deficits. Treatment-related side effects (e.g., chemotherapy-induced neuropathy, immunotherapy-related cytokine release syndrome) further compromise functional status and daily living activities. Early diagnosis remains challenging due to nonspecific symptoms mimicking benign conditions (e.g., mononucleosis, chronic fatigue syndrome), underscoring the need for heightened clinical suspicion and timely referral to hematology specialists for comprehensive evaluation—including biopsy, flow cytometry, molecular profiling, and PET-CT staging.

# 淋巴瘤治疗方案与费用明细（血液科）

一、非手术/药物/保守治疗方案

适用人群：初治惰性B细胞淋巴瘤（如滤泡性淋巴瘤Ⅰ–Ⅱ期）、老年或合并严重基础病者、维持治疗阶段患者。

• •一线免疫化疗（R-CHOP）：利妥昔单抗+环磷酰胺+多柔比星+长春新碱+泼尼松，6–8周期

- 血常规、LDH、β2微球蛋白、骨髓穿刺活检、PET-CT（基线+疗效评估）：1.3万–2.1万元

• •靶向单药维持（如来那度胺）或BTK抑制剂（伊布替尼）：适用于复发/难治CLL/SLL

二、核心介入/根治性治疗方案

适用人群：侵袭性淋巴瘤（DLBCL、间变大细胞淋巴瘤等）初治高危患者；自体造血干细胞移植（ASCT）候选者。

• •ASCT全流程（含动员、采集、预处理、回输、支持治疗）

- 全套费用（不含并发症）：28万–45万元（三甲血液中心标准收费）

三、特殊复杂/晚期/耐药方案

• •CAR-T细胞治疗（如泽布替尼联合CAR-T或二线CAR-T）：120万–150万元（含制备、回输、ICU监护及CRS管理）
• •放疗联合靶向（如纵隔大肿块局部放疗+PD-1抑制剂）：6.5万–11万元（含模拟定位、计划设计、25次照射）

方案快速选择指南

✅ 预算≤5万元：优选R-CHOP门诊化疗（医保报销后自付约1–2万元） ✅ 预算15–30万元+中高危初治：ASCT为根治首选 ✅ 复发/耐药/≥65岁：BTKi或CAR-T（需评估ECOG评分及器官储备）